Therapeutic Potential of GLP-2 Analogs in Gastrointestinal Disorders: Current Knowledge, Nutritional Aspects, and Future Perspectives
- 6 August 2022
- journal article
- review article
- Published by Springer Nature in Current Nutrition Reports
- Vol. 11 (4) , 618-642
Abstract
Purpose of Review Although Glucagon-like peptide (GLP)-1 receptor agonists have been used for almost two decades in the treatment of diabetes mellitus type 2 and, lately, in obesity, recent years have seen an increasing interest in the pharmacological agonism of other proglucagon-derived peptides, including GLP-2. Herein, we aimed to review the available evidence on the effects of GLP-2 agonism from animal and clinical studies. Furthermore, we summarize the current clinical applications of GLP-2 agonists among patients with intestinal failure associated with short bowel syndrome (SBS-IF) as well as potential future expansion of their indications to other intestinal disorders. Recent Findings Evidence from preclinical studies has highlighted the cellular trophic and functional beneficial actions of GLP-2 on small intestinal and colonic mucosa. Subsequently, pharmacologic agonism of GLP-2 has gathered interest for the treatment of patients with conditions pertaining to the loss of intestinal anatomical and/or functional integrity to a degree requiring parenteral support, collectively referred to as intestinal failure. GLP-2 analogs positively influence nutrient absorption in animal models and humans, although continued therapy is likely needed for sustained effects. The degradation-resistant GLP-2-analog teduglutide has received approval for the treatment of SBS-IF, in which it may decisively reduce patient dependency on parenteral support and improve quality of life. Another two longer-acting analogs, glepaglutide and apraglutide, are currently undergoing phase III clinical trials. Summary The use of GLP-2 analogs is effective in the management of SBS-IF and may show promise in the treatment of other severe gastrointestinal disorders associated with loss of effective intestinal resorptive surface area.Keywords
This publication has 103 references indexed in Scilit:
- Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide – Analyses from a randomised, placebo-controlled studyClinical Nutrition, 2013
- Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseNew England Journal of Medicine, 2013
- Disruption of the Murine Glp2r Impairs Paneth Cell Function and Increases Susceptibility to Small Bowel EnteritisEndocrinology, 2012
- Insulin-like growth factor 1Current Opinion in Gastroenterology, 2012
- Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndromeGut, 2011
- Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeabilityGut, 2009
- Glucagon-Like Peptide-2 Improves Both Acute and Late Experimental Radiation Enteritis in the RatInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Glucagon-like Peptide-2 Induces a Specific Pattern of Adaptation in Remnant JejunumDigestive Diseases and Sciences, 2006
- Comparative Effects of Glucagon‐Like Peptide‐2 (GLP‐2), Growth Hormone (GH), and Keratinocyte Growth Factor (KGF) on Markers of Gut Adaptation After Massive Small Bowel Resection in RatsJournal of Parenteral and Enteral Nutrition, 2004
- GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1 1This work is a publication of the USDA/ARS Children’s Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, Houston, Texas.Gastroenterology, 2003